|
Latin America has a number of advantages when it comes to clinical trial activity. The patient enrollment is three to five times greater per site than in traditional regions such as Western Europe and the United States, while the patient discontinuation rate is one-third that of traditional regions.
Another benefit of Latin America is “seasonal reversal'. For example, when it’s winter in the United States and Europe, allergy studies can be conducted in Latin America. With similar time zones to the United States, Latin America also offers quick and easy communication with U.S. customers and partners.
Latin America also provides access to unique populations such as pediatric patients, which are increasingly required for global studies. For example, in Mexico, out of a population of 107 million people, 44 percent are under age 18 and 37 percent are under age 15. Similarly, in Brazil, 38 percent of the population of 187 million is under the age of 18. These populations create huge opportunities for pediatric studies.
Top reasons to conduct a clinical trial in Latin America
- Pediatric expertise – Latin America has nearly 250 million pediatric patients – 44 percent of its population.
- Solid regulatory framework – the six countries where Kendle is focusing its operations (combined population of 420 million people) have predictable timelines and reliable processes in line with international GCP guidelines.
- High quality data – this is proven by FDA inspections and sponsor audits.
- Hispanic population – data from this population is generally under-represented in NDAs and can be enhanced through conducting studies in Latin America.
- Expedited enrollment – on average the enrollment rate in Latin America is three to five times greater per site than in traditional regions. This leads to faster completion times and reduced costs.
|
